15.07.2010 • News

Novartis in $175 Million Gender Bias Settlement

Novartis has agreed to pay $175 million to settle a class-action lawsuit accusing the Swiss drugmaker of discriminating against 5,600 current and former female employees.

The settlement was announced less than two months after a Manhattan jury ordered Novartis to pay $250 million in punitive damages, after a six-week trial. That jury concluded the company's U.S. unit, Novartis Pharmaceuticals, engaged in a pattern of discrimination between 2002 and 2007.

Lawyers for the plaintiffs said it was the largest U.S. gender discrimination case ever to go to trial. In a joint statement with the plaintiffs' lawyers, Novartis said it will pay $152.5 million to eligible class members and pay an additional $22.5 million to improve companywide complaint processes, oversight and performance assessment.

The settlement requires court approval. U.S. District Judge Colleen McMahon scheduled a Nov. 19 hearing to consider whether to approve it.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.